Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: A 5-year prospective study of 1755 patients

Gut

Volumn 68, Issue 1, 2019, Pages 11-17

  Rugge, Massimo ^a,b   Meggio, Alberto ^c   Pravadelli, Cecilia ^c   Barbareschi, Mattia ^d   Fassan, Matteo ^a   Gentilini, Maria ^e   Zorzi, Manuel ^b   De Pretis, Giovanni ^c   Graham, David Y ^f   Genta, Robert M ^f,g  

^a UNIVERSITY OF PADOVA   (Italy)

^b Tumor Registry of the Veneto Region   (Italy)

^c Trento and Rovereto Hospital ^*  (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e Osservatorio Epidemiologico   (Italy)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g MIRACA LIFE SCIENCES   (United States)

Author keywords

gastric cancer; gastritis; helicobacter pylori; pre malignancy gi tract

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; DYSPEPSIA; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; FOLLOW UP; GASTRITIS; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAEPITHELIAL NEOPLASIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY PREVENTION; STAGING; STOMACH BIOPSY; STOMACH CANCER; STOMACH TUMOR; VERY ELDERLY; ADOLESCENT; ATROPHIC GASTRITIS; BIOPSY; CANCER STAGING; DIGESTIVE TRACT ENDOSCOPY; DISEASE EXACERBATION; ITALY; MIDDLE AGED; PATHOLOGY; PRECANCER; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DISEASE PROGRESSION; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; FOLLOW-UP STUDIES; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS;

EID: 85049111509     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-314600     Document Type: Article

References (50)

1. Colquhoun A, Arnold M, Ferlay J, et al. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut 2015;64:1881-8.
2. International Agency for Research on Cancer. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC working group reports. 8 ed. Geneva, Switzerland: WHO Press, World Health Organization, 2014.
3. Correa P, Piazuelo MB. Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev 2011;7:59-64.
4. den Hoed CM, Kuipers EJ. Gastric cancer: how can we reduce the incidence of this disease? Curr Gastroenterol Rep 2016;18:34.
5. Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol 2014;20:5191-204.
6. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-31.
7. Lee YC, Chiang TH, Chou CK, et al. Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016;150:1113-24.
8. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of helicobacter pylori infection-the maastricht IV/ florence consensus report. Gut 2012;61:646-64.
9. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of helicobacter pylori infection-the maastricht V/florence consensus report. Gut 2017;66:6-30.
10. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
11. Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol 2013;10:495-500.
12. Graham DY. Helicobacter pylori eradication and metachronous gastric cancer. Clin Gastroenterol Hepatol 2014;12:801-3.
13. Shiotani A, Haruma K, Graham DY. Metachronous gastric cancer after successful Helicobacter pylori eradication. World J Gastroenterol 2014;20:11552-9.
14. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ 2004:301-10.
15. Kong YJ, Yi HG, Dai JC, et al. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol 2014;20:5903-11.
16. Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015;20:25-40.
17. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40:650-8.
18. Rugge M, Genta RM, Graham DY, et al. Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. Gut 2016;65:721-5.
19. Miwata T, Quach DT, Hiyama T, et al. Interobserver and intraobserver agreement for gastric mucosa atrophy. BMC Gastroenterol 2015;15:95.
20. Neumann WL, Coss E, Rugge M, et al. Autoimmune atrophic gastritis-pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013;10:529-41.
21. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002;16:1249-59.
22. Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment gastritis staging incorporates intestinal metaplasia subtyping. Hum Pathol 2011;42:1539-44.
23. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000;24:167-76.
24. Areia M, Carvalho R, Cadime AT, et al. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter 2013;18:325-37.
25. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Virchows Arch 2012;460:19-46.
26. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on helicobacter pylori gastritis. Gut 2015;64:1353-67.
27. Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of helicobacter pylori infection in Italy: the III working group consensus report 2015. Dig Liver Dis 2015;47:903-12.
28. Marques-Silva L, Areia M, Elvas L, et al. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2014;26:378-87.
29. Mera RM, Bravo LE, Camargo MC, et al. Dynamics of helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. In Press. 2017:gutjnl-2016-311685.
30. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150-8.
31. Nam JH, Choi IJ, Kook MC, et al. OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population. Helicobacter 2014;19:81-9.
32. Rugge M, Capelle LG, Cappellesso R, et al. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 2013;27:205-23.
33. Rugge M, Capelle LG, Fassan M. Individual risk stratification of gastric cancer: evolving concepts and their impact on clinical practice. Best Pract Res Clin Gastroenterol 2014;28:1043-53.
34. Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010;31:1104-11.
35. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol 2005;36:228-33.
36. Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;56:631-6.
37. Rugge M, Pennelli G, Pilozzi E, et al. Gastritis: the histology report. Dig Liver Dis 2011;43(Suppl 4):S373-S384.
38. Satoh K, Osawa H, Yoshizawa M, et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter 2008;13:225-9.
39. Zhou Y, Li HY, Zhang JJ, et al. Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer. World J Gastroenterol 2016;22:3670-8.
40. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
41. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
42. Rugge M, Leandro G, Farinati F, et al. Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer 1995;76:376-82.
43. de Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 2009;104:1342-5.
44. Kuipers EJ. When is endoscopic follow-up appropriate after helicobacter pylori eradication therapy? Gastroenterol Clin North Am 2015;44:597-608.
45. Rugge M, de Boni M, Pennelli G, et al. OLGA can guard the barn. Am J Gastroenterol 2009;104:3099.
46. Rugge M. Gastric cancer risk in patients with helicobacter pylori infection and following its eradication. Gastroenterol Clin North Am 2015;44:609-24.
47. Saka A, Yagi K, Nimura S. OLGA- and OLGIM-based staging of gastritis using narrowband imaging magnifying endoscopy. Dig Endosc 2015;27:735-42.
48. Tsukanov VV, Butorin NN, Maady AS, et al. Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in Eastern Siberia. Helicobacter 2011;16:107-12.
49. Eun CS, Kim BK, Han DS, et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter 2014;19:407-16.
50. Yu G, Hu N, Wang L, et al. Gastric microbiota features associated with cancer risk factors and clinical outcomes: a pilot study in gastric cardia cancer patients from Shanxi, China. Int J Cancer 2017;141:45-51.